Cargando…

Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells

Although the differentiation of human induced pluripotent stem cells (hiPSCs) into various types of blood cells has been well established, approaches for clinical-scale production of multipotent hematopoietic progenitor cells (HPCs) remain challenging. We found that hiPSCs cocultured with stromal ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaoki, Naritaka, Siebert, Stefan, Maeda, Takuya, Ha, Ngoc-Han, Good, Meghan L., Huang, Yin, Vodnala, Suman K., Haro-Mora, Juan J., Uchida, Naoya, Tisdale, John F., Sweeney, Colin L., Choi, Uimook, Brault, Julie, Koontz, Sherry, Malech, Harry L., Yamazaki, Yasuhiro, Isonaka, Risa, Goldstein, David S., Kimura, Masaki, Takebe, Takanori, Zou, Jizhong, Stroncek, David F., Robey, Pamela G., Kruhlak, Michael J., Restifo, Nicholas P., Vizcardo, Raul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163025/
https://www.ncbi.nlm.nih.gov/pubmed/37159663
http://dx.doi.org/10.1016/j.crmeth.2023.100460
Descripción
Sumario:Although the differentiation of human induced pluripotent stem cells (hiPSCs) into various types of blood cells has been well established, approaches for clinical-scale production of multipotent hematopoietic progenitor cells (HPCs) remain challenging. We found that hiPSCs cocultured with stromal cells as spheroids (hematopoietic spheroids [Hp-spheroids]) can grow in a stirred bioreactor and develop into yolk sac-like organoids without the addition of exogenous factors. Hp-spheroid-induced organoids recapitulated a yolk sac-characteristic cellular complement and structures as well as the functional ability to generate HPCs with lympho-myeloid potential. Moreover, sequential hemato-vascular ontogenesis could also be observed during organoid formation. We demonstrated that organoid-induced HPCs can be differentiated into erythroid cells, macrophages, and T lymphocytes with current maturation protocols. Notably, the Hp-spheroid system can be performed in an autologous and xeno-free manner, thereby improving the feasibility of bulk production of hiPSC-derived HPCs in clinical, therapeutic contexts.